Journal of Clinical & Experimental Pharmacology

Novel Biomarker for the Diagnosis and Prognosis of Acute Alcoholic Hepatitis

Vatsalya Vatsalya^{1,2,3* 1}Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville KY, USA
²Robley Rex VA Medical Center, Louisville KY, USA
³University of Louisville Alcohol Research Center, Louisville KY, USA
^*Correspondence: Vatsalya Vatsalya, MD, MS, PgD, MSc, Department of Medicine, Pharmacology, and Toxicology, University of Louisville School of Medicine, 505 S. Hancock St., Suite 514A, Louisville, KY, 40202, USA, Tel: 502-852-8928, Fax: 502-852-8927, Email:

Received: 28-Sep-2019 Published: 28-Jul-2020

Abbreviations

AAH: Acute Alcoholic Hepatitis; ALD: Alcoholic Liver Disease; ALT: Alanine Aminotransferase; AUD: Alcohol Use Disorder; AST: Aspartate Aminotransferase; CK 18: Cytokeratin 18

Editorial

Alcohol use disorder (AUD) characterized by heavy and prolonged alcohol intake could cause various forms of alcoholic liver disease (ALD). The spectrum of alcoholic liver disease (ALD) consists of steatosis, steatohepatitis, cirrhosis and hepatocellular carcinoma depending on the duration and severity of alcohol intake [1,2]. Interestingly only one-third of heavy drinkers (typically a sub-group of AUD patients), who exhibit specific heavy drinking patterns [3,4] would develop any clinically relevant form of liver damage. However, only 10 to 15% of all drinkers develop severe forms of ALD. While numerous biomarkers have been identified with the diagnoses of early stage, and advanced form of ALD; no specific biomarker has described the staging, severity and prognosis clearly. Acute alcoholic hepatitis (AAH), an advanced form of ALD is a major cause of liver related morbidity and mortality. Established markers of liver damage (AST, ALT) are highly nonspecific and are affected by a wide array of pathologies. This creates a gap in the understanding of advanced forms of ALD, for example alcoholic hepatitis. New biomarkers are being tested to determine the degree of ongoing liver pathology and prognosis; and could be used in deciding the appropriate treatment. A non-invasive biomarker, extracellular cytokeratin 18 (K18) has recently been reported to have substantial association with the degree and severity of liver injury and liver cell death in ALD. Cytokeratin 18 (K18) is a death marker for epithelial cell, and their serum concentrations could be very high following hepatocyte death [5]. During cell death, loss of cell membrane integrity could be consequential in the release of intracellular proteins (including K18), into the extracellular compartment. K18 is a substrate cleaved by caspase-3, and the cleaved form of K18 is K18M30 that determines the degree of apoptosis. K18M65 is a biomarker for necrosis (both the caspasecleaved and uncleaved forms). Both M65 and M30 can be detected in plasma using ELISA testing [6]. Bissonnette et al. [7] compared M65 and M30 levels to the histologically confirmed cases of alcoholic hepatitis with significantly positive results including a positive predictive value of 91% at a M65 cutoff of 2000 IU/L with a 81% accuracy in diagnosis. In a recent study, Keratin 18 appears to reflect the degree of hepatocyte death and delineate liver disease severity better than other traditional biomarkers, such as AST, ALT, and the AST:ALT ratio [8]. ALD is a leading cause of reversible morbidity and mortality. However, significant advancement is needed to characterize AAH presentation in context of the ongoing liver injury and liver cell death. Medical management of AAH will eventually involve the use of biomarkers (like K18) that could accurately reflect the clinical presentation for diagnosis, and prognosis of the disease severity.

Conflicts of Interest

Author declares no conflicts of interest.

Proprietorship

This article is a work of the Alcohol Research Center of the University of Louisville and is in the public domain in the USA.

Financial/Grant Support

NIH supported - Z99-AA999999 (VV), U01AA021901, U01AA021893-01, U01AA022489-01A1 (CJM). The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.

REFERENCES

1. Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis 1988;8:12-25.
2. Savolainen VT, Liesto K, Manniko A, Penttila A, Karhunen PJ. Alcohol consumption and alcoholic liver disease: evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res 1993;17:1112-1117.
3. Vatsalya V, Song M, Schwandt ML, Cave MC, Barve SS, George DT, et al. Effects of sex, drinking history, and omega‐3 and omega‐6 fatty acids dysregulation on the onset of liver injury in very heavy drinking alcohol‐dependent patients. Alcohol Clin Exp Res 2016;40:2085-2093.
4. Vatsalya V, Kong M, Gobejishvili L, Chen WY, Srivastava S, Barve S, et al. Urinary acrolein metabolite levels in severe acute alcoholic hepatitis patients. Am J Physiol Gastrointest Liver Physiol 2019;316:G115-G122.
5. Ku NO, Strnad P, Bantel H, Omary MB. Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology 2016;64:966-976.
6. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarker for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology 2009;50:1072-1078.
7. Bissonnette J, Altamirano J, Devue C, Roux O, Payancé A, Lebrec D, et al. A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. Hepatology 2017;66:555-563.
8. Vatsalya V, Heather C, Keith CF, Matthew CC, McClain CJ. Efficacy of Keratin 18 (CK18) as a Biomarker of Severity of Liver Injury in Acute Alcoholic Hepatitis. Gastroenterology 2017;152:S1110-S1111.